Dermal fibroblast collagen synthesis pathway

Dermal fibroblasts are the primary mesenchymal cells in the skin's dermis, responsible for the production and maintenance of the extracellular matrix (ECM), with collagen types I and III being the most abundant components (Frontiers, 2025). The collagen synthesis pathway in these cells is a highly regulated process primarily controlled by the Transforming Growth Factor-beta (TGF-beta)/SMAD signaling axis, which drives the transcription of procollagen genes like COL1A1 (PubMed: 7533764). This pathway is essential for maintaining skin structural integrity, elasticity, and the regenerative response during wound healing (PMC: 1024567). In pathological states, the pathway's activity is often altered: a progressive decline in collagen synthesis and increased degradation by matrix metalloproteinases (MMPs) characterize skin aging and photoaging, while its chronic over-activation leads to fibrotic disorders such as keloids, hypertrophic scars, and systemic sclerosis (Jipu et al., 2025). Therapeutic strategies targeting this pathway include retinoids and growth factors to stimulate collagen production for aesthetic rejuvenation, as well as antifibrotic agents like tranilast and pirfenidone to suppress excessive ECM deposition in scarring and inflammatory skin diseases (PatSnap, 2026).

Other names

Fibroblast collagen productionDermal extracellular matrix synthesis pathwaySkin collagen biosynthetic process

Activation of TGF-beta/SMAD signaling, inhibition of matrix metalloproteinases (MMPs), stimulation of prolyl hydroxylase activity, and modulation of fibroblast-to-myofibroblast differentiation.